Page 6 - 2021_09-Haematologica-web
P. 6
Table of Contents
Volume 106, Issue 9: September 2021
About the Cover
haematologica Journal of the Ferrata Storti Foundation
2297 Images from the Haematologica Atlas of Hematologic Cytology: primary myelofibrosis, micromegakaryocytic transformation Rosangela Invernizzi
https://doi.org/10.3324/haematol.2021.279315
Editorials
2298 Preventing central nervous system spread in diffuse large B-cell lymphoma – novel approaches needed Mark Roschewski
https://doi.org/10.3324/haematol.2021.278559
2300 All in the family: back-to-back kinase inhibitors for the treatment of chronic lymphocytic leukemia Meghan C. Thompson et al.
https://doi.org/10.3324/haematol.2021.278535
2302 Do we need more genome wide association studies? Stephan Menzel
https://doi.org/10.3324/haematol.2021.278642
Review Articles
2304 Towards manufactured red blood cells for the treatment of inherited anemia Stephanie Pellegrin et al.
https://doi.org/10.3324/haematol.2020.268847
2312 Targeting the tumor microenvironment in chronic lymphocytic leukemia Rebecka Svanberg et al.
https://doi.org/10.3324/haematol.2020.268037
Articles
Acute Myeloid Leukemia
2325 Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse
Esther Onecha et al.
https://doi.org/10.3324/haematol.2020.254623
Chronic Lymphocytic Leukemia
2334 Three-dimensional co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents
Federica Barbaglio et al. https://doi.org/10.3324/haematol.2020.248112
2345 Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukemia
Giovanni Del Poeta et al. https://doi.org/10.3324/haematol.2020.251488
2354 Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion Constantine S. Tam et al.
https://doi.org/10.3324/haematol.2020.259432
2364 Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia Kerry A. Rogers et al.
https://doi.org/10.3324/haematol.2020.272500
Haematologica 2021; vol. 106 no. 9 - September 2021 http://www.haematologica.org/
